Health and economic effects of introducing single-dose or two-dose human papillomavirus vaccination in India
Background Cervical cancer is a major public health problem in India, where access to prevention programmes is low. The WHO-Strategic Advisory Group of Experts recently updated their recommendation for human papillomavirus (HPV) vaccination to include a single-dose option in addition to the two-dose...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-11-01
|
| Series: | BMJ Global Health |
| Online Access: | https://gh.bmj.com/content/8/11/e012580.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850057143524261888 |
|---|---|
| author | Partha Basu Rengaswamy Sankaranarayanan Ishu Kataria Johannes Berkhof Eric Lucas Lopamudra Ray Saraswati Iacopo Baussano Richard Muwonge Johannes A Bogaards Tiago M de Carvalho Irene Man Damien Georges Prince Bhandari Mariam Siddiqui |
| author_facet | Partha Basu Rengaswamy Sankaranarayanan Ishu Kataria Johannes Berkhof Eric Lucas Lopamudra Ray Saraswati Iacopo Baussano Richard Muwonge Johannes A Bogaards Tiago M de Carvalho Irene Man Damien Georges Prince Bhandari Mariam Siddiqui |
| author_sort | Partha Basu |
| collection | DOAJ |
| description | Background Cervical cancer is a major public health problem in India, where access to prevention programmes is low. The WHO-Strategic Advisory Group of Experts recently updated their recommendation for human papillomavirus (HPV) vaccination to include a single-dose option in addition to the two-dose option, which could make HPV vaccination programmes easier to implement and more affordable.Methods We combined projections from a type-specific HPV transmission model and a cancer progression model to assess the health and economic effects of HPV vaccination at national and state level in India. The models used national and state-specific Indian demographic, epidemiological and cost data, and single-dose vaccine efficacy and immunogenicity data from the International Agency for Research on Cancer India vaccine trial with 10-year follow-up. We compared single-dose and two-dose HPV vaccination for a range of plausible scenarios regarding single-dose vaccine protection, coverage and catch-up. We used a healthcare sector payer perspective with a time horizon of 100 years.Results Under the base-case scenario of lifelong protection of single-dose vaccination in 10-year-old girls with 90% coverage, the discounted incremental cost-effectiveness ratio (ICER) of nationwide vaccination relative to no vaccination was US$406 (₹INR30 000) per DALY (disability-adjusted life-years) averted. This lay below an opportunity-cost-based threshold of 30% Indian gross domestic product per capita in each Indian state (state-specific ICER range: US$67–US$593 per DALY averted). The ICER of two-dose vaccination versus no vaccination vaccination was US$1404 (₹INR104 000). The ICER of two-dose vaccination versus single-dose vaccination, assuming lower initial efficacy and waning of single-dose vaccination, was at least US$2282 (₹INR169 000) per DALY averted.Conclusions Nationwide introduction of single-dose HPV vaccination at age 10 in India is highly likely to be cost-effective whereas extending the number of doses from one to two would have a less favourable profile. |
| format | Article |
| id | doaj-art-2ed21aa7ad664d4086bb34c6a82af48c |
| institution | DOAJ |
| issn | 2059-7908 |
| language | English |
| publishDate | 2023-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Global Health |
| spelling | doaj-art-2ed21aa7ad664d4086bb34c6a82af48c2025-08-20T02:51:31ZengBMJ Publishing GroupBMJ Global Health2059-79082023-11-0181110.1136/bmjgh-2023-012580Health and economic effects of introducing single-dose or two-dose human papillomavirus vaccination in IndiaPartha Basu0Rengaswamy Sankaranarayanan1Ishu Kataria2Johannes Berkhof3Eric Lucas4Lopamudra Ray Saraswati5Iacopo Baussano6Richard Muwonge7Johannes A Bogaards8Tiago M de Carvalho9Irene Man10Damien Georges11Prince Bhandari12Mariam Siddiqui13International Agency for Research on Cancer, Lyon, France4 Karkinos Healthcare, Ernakulam, India3 Research Triangle Institute (RTI) International India, New Delhi, India1 Department of Epidemiology and Data Science, Amsterdam UMC VUMC Site, Amsterdam, The Netherlands2 Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer, Lyon, France3 Research Triangle Institute (RTI) International India, New Delhi, India2 Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer, Lyon, France2 Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer, Lyon, France1 Department of Epidemiology and Data Science, Amsterdam UMC VUMC Site, Amsterdam, The Netherlands1 Department of Epidemiology and Data Science, Amsterdam UMC VUMC Site, Amsterdam, The Netherlands2 Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer, Lyon, France2 Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer, Lyon, France3 Research Triangle Institute (RTI) International India, New Delhi, India3 Research Triangle Institute (RTI) International India, New Delhi, IndiaBackground Cervical cancer is a major public health problem in India, where access to prevention programmes is low. The WHO-Strategic Advisory Group of Experts recently updated their recommendation for human papillomavirus (HPV) vaccination to include a single-dose option in addition to the two-dose option, which could make HPV vaccination programmes easier to implement and more affordable.Methods We combined projections from a type-specific HPV transmission model and a cancer progression model to assess the health and economic effects of HPV vaccination at national and state level in India. The models used national and state-specific Indian demographic, epidemiological and cost data, and single-dose vaccine efficacy and immunogenicity data from the International Agency for Research on Cancer India vaccine trial with 10-year follow-up. We compared single-dose and two-dose HPV vaccination for a range of plausible scenarios regarding single-dose vaccine protection, coverage and catch-up. We used a healthcare sector payer perspective with a time horizon of 100 years.Results Under the base-case scenario of lifelong protection of single-dose vaccination in 10-year-old girls with 90% coverage, the discounted incremental cost-effectiveness ratio (ICER) of nationwide vaccination relative to no vaccination was US$406 (₹INR30 000) per DALY (disability-adjusted life-years) averted. This lay below an opportunity-cost-based threshold of 30% Indian gross domestic product per capita in each Indian state (state-specific ICER range: US$67–US$593 per DALY averted). The ICER of two-dose vaccination versus no vaccination vaccination was US$1404 (₹INR104 000). The ICER of two-dose vaccination versus single-dose vaccination, assuming lower initial efficacy and waning of single-dose vaccination, was at least US$2282 (₹INR169 000) per DALY averted.Conclusions Nationwide introduction of single-dose HPV vaccination at age 10 in India is highly likely to be cost-effective whereas extending the number of doses from one to two would have a less favourable profile.https://gh.bmj.com/content/8/11/e012580.full |
| spellingShingle | Partha Basu Rengaswamy Sankaranarayanan Ishu Kataria Johannes Berkhof Eric Lucas Lopamudra Ray Saraswati Iacopo Baussano Richard Muwonge Johannes A Bogaards Tiago M de Carvalho Irene Man Damien Georges Prince Bhandari Mariam Siddiqui Health and economic effects of introducing single-dose or two-dose human papillomavirus vaccination in India BMJ Global Health |
| title | Health and economic effects of introducing single-dose or two-dose human papillomavirus vaccination in India |
| title_full | Health and economic effects of introducing single-dose or two-dose human papillomavirus vaccination in India |
| title_fullStr | Health and economic effects of introducing single-dose or two-dose human papillomavirus vaccination in India |
| title_full_unstemmed | Health and economic effects of introducing single-dose or two-dose human papillomavirus vaccination in India |
| title_short | Health and economic effects of introducing single-dose or two-dose human papillomavirus vaccination in India |
| title_sort | health and economic effects of introducing single dose or two dose human papillomavirus vaccination in india |
| url | https://gh.bmj.com/content/8/11/e012580.full |
| work_keys_str_mv | AT parthabasu healthandeconomiceffectsofintroducingsingledoseortwodosehumanpapillomavirusvaccinationinindia AT rengaswamysankaranarayanan healthandeconomiceffectsofintroducingsingledoseortwodosehumanpapillomavirusvaccinationinindia AT ishukataria healthandeconomiceffectsofintroducingsingledoseortwodosehumanpapillomavirusvaccinationinindia AT johannesberkhof healthandeconomiceffectsofintroducingsingledoseortwodosehumanpapillomavirusvaccinationinindia AT ericlucas healthandeconomiceffectsofintroducingsingledoseortwodosehumanpapillomavirusvaccinationinindia AT lopamudraraysaraswati healthandeconomiceffectsofintroducingsingledoseortwodosehumanpapillomavirusvaccinationinindia AT iacopobaussano healthandeconomiceffectsofintroducingsingledoseortwodosehumanpapillomavirusvaccinationinindia AT richardmuwonge healthandeconomiceffectsofintroducingsingledoseortwodosehumanpapillomavirusvaccinationinindia AT johannesabogaards healthandeconomiceffectsofintroducingsingledoseortwodosehumanpapillomavirusvaccinationinindia AT tiagomdecarvalho healthandeconomiceffectsofintroducingsingledoseortwodosehumanpapillomavirusvaccinationinindia AT ireneman healthandeconomiceffectsofintroducingsingledoseortwodosehumanpapillomavirusvaccinationinindia AT damiengeorges healthandeconomiceffectsofintroducingsingledoseortwodosehumanpapillomavirusvaccinationinindia AT princebhandari healthandeconomiceffectsofintroducingsingledoseortwodosehumanpapillomavirusvaccinationinindia AT mariamsiddiqui healthandeconomiceffectsofintroducingsingledoseortwodosehumanpapillomavirusvaccinationinindia |